Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Next Previous
Trial Profile

A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Seagen; Seattle Genetics

Most Recent Events

  • 21 Jun 2020 Results assessing Impact of Nivolumab on Overall Survival in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from two clinical studies presented at the 25th Congress of the European Haematology Association
  • 15 May 2020 According to a Takeda China media release, ADCETRIS (brentuximab vedotin) has been officially approved by Chinas National Medical Products Administration (NMPA) for use in adult patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (sALCL) or CD30-positive Hodgkin Lymphoma. The local approval of ADCETRIS in China is based on the data from clinical studies SG035-0004, SG035-0003 and C25007.
  • 06 Nov 2019 Results of MAIC analysis (matching adjusted indirect comparison) of two clinical trials CheckMate 205 or NCT02181738 (n=306) and NCT00848926 (n=102) assesing efficacy and survival benefit of nivolumab relative to Brentuximab vedotin in relapsed/refractory classical hodgkin lymphoma, released in 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top